Cushing’s syndrome is a disorder that occurs when your body makes too much of the hormone cortisol over a long period of time. Cortisol is sometimes called the “stress hormone” because it helps your body respond to stress.
In a recent press release, Recordati Rare Diseases announced the results from a Phase III study of Isturisa® (Osilodrostat) published in Lancet Diabetes and Endocrinology. “The exciting data, published today, underscore the efficacy and safety
From Leslie Edwin, President of CSRF and PWN Contributor – On June 18, 2020, online medical journal The Lancet Diabetes and Endocrinology published a report about the association between high cortisol and death rate with COVID-19.
In this engaging podcast about the diagnosis of Cushing’s syndrome, Pituitary Worlds News co-founder and Medical Director, California Center for Pituitary Disorders at UCSF Professor of Clinical Medicine and Clinical Neurological Surgery, Dr. Lewis Blevins
This is a series of urgent clinical guidance documents on the management of endocrine conditions in the time of COVID-19. This clinical guidance document underwent expedited open peer review by Jérôme Bertherat (Paris, France), André
In this podcast, Dr. Lewis Blevins discusses a new drug for Cushing’s disease recently approved in the US.
We caught up with Dr. Kevin Yuen, medical director of the Barrow Pituitary Center and the Barrow Neuroendocrinology Clinic in Phoenix, Arizona, and Dr. Lewis Blevins Medical Director of the California Center for Pituitary Disorders at
This article on Cushing’s disease provides a concise, excellent overview of the optimal management and highlights of both surgical and medical advances. Click here to read the article. There are also helpful links to resources
From the Desk of Leslie Edwin, President of CSRF and PWN Contributor – We have just completed an intimate, four-video series of first-hand accounts of the Cushing’s journey. They can be found, along with recorded sessions
This is the first in a series of 6 podcasts on the ins and outs of drug development. In it, we discuss the journey that a promising molecule takes to develop into a life-saving medication and
The CSRF has published materials from their recent Patient Journey Summit,”Defining the New Normal” The topics for the conference, held October 4-6, 2019 at Emory Conference Center Hotel in Atlanta, were organized by a patient-led group. The group
The World Alliance of Pituitary Organizations (WAPO) will participate in the upcoming Cushing’s Support and Research Foundation (CSRF) conference slated for October 4 to 6 in Atlanta, Georgia. Muriel Marks, WAPO’s Executive Director, will present
In a press release, Strongbridge Biopharma announced comprehensive positive results of their Phase 3 SONICS study of RECORLEVTM (levoketoconazole) for the potential treatment of endogenous Cushing’s syndrome. The results were published online in The Lancet